Comparative Pharmacology
Head-to-head clinical analysis: BETA HC versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA HC versus HC 1.
BETA-HC vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Unknown
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
2–4 hours (terminal); prolonged in renal impairment.
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid